US2023348521A1PendingUtilityA1
Methods of synthesizing nicotinamide riboside
Est. expiryJun 30, 2037(~10.9 yrs left)· nominal 20-yr term from priority
C07H 19/048C07H 1/06C12P 19/385
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are efficient and scalable methods for the synthesis of nicotinamide riboside from riboside triacetate. Also provided are compositions comprising nicotinamide riboside, and therapeutic methods employing nicotinamide riboside.
Claims
exact text as granted — not AI-modified1 . A method of preparing compound 3, comprising the steps of:
(a) combining compound 1 and a chlorinating agent, thereby producing a first reaction mixture comprising compound 2, wherein:
compound 1 is represented by
compound 2 is represented by
and
the chlorinating agent is gaseous HCl or HCl in dioxane; and
(b) combining compound 2 with nicotinamide, thereby producing a second reaction mixture comprising compound 3.
2 - 27 . (canceled)
28 . A method of preparing compound 4,
comprising the steps of:
(c) combining compound 3 with an ammonia reagent, thereby producing a first reaction mixture comprising compound 4, wherein:
compound 3 is represented by
and
the ammonia reagent is methanolic ammonia or diethylamine.
29 . The method of claim 28 , wherein the ammonia reagent is diethylamine.
30 . The method of claim 28 , wherein the ammonia reagent is methanolic ammonia.
31 . (canceled)
32 . The method of claim 28 , wherein step (c) occurs in a third solvent.
33 . The method of claim 32 , wherein the third solvent is methanol.
34 . The method of claim 28 , wherein step (c) takes place at a temperature below room temperature.
35 . The method of claim 28 , wherein the ammonia reagent is diethylamine;
further comprising step (c′), which occurs after step (c): (c′) adding cold aqueous HCl to the third reaction mixture, thereby producing a fourth mixture comprising compound 4.
36 . The method of claim 28 , wherein the ammonia reagent is methanolic ammonia;
further comprising step (c′), which occurs after step (c): (c′) concentrating the third reaction mixture under reduced atmospheric pressure, thereby producing a fourth mixture comprising compound 4.
37 . The method of claim 35 , further comprising step (c″), which occurs after step (c′):
(c″) filtering the fourth mixture.
38 . The method of claim 37 , further comprising rinsing the retentate with cold methanol or ethanol.
39 . The method of claim 37 , further comprising rinsing the retentate with cold acetone.
40 . The method of claim 28 , further comprising
(a) combining compound 1 and a chlorinating agent, thereby producing a first reaction mixture comprising compound 2, wherein:
compound 1 is represented by
compound 2 is represented by
and
the chlorinating agent is gaseous HCl or HCl in dioxane; and
(b) combining compound 2 with nicotinamide, thereby producing a second reaction mixture comprising compound 3.
41 - 54 . (canceled)
55 . Compound 4, made according to method of claim 28 .
56 . (canceled)
57 . (canceled)
58 . A method of improving cellular health in a subject, comprising administering to the subject a compound of claim 55 .
59 . A method of improving sleep quality, stimulating or increasing REM sleep, or treating or preventing insomnia, desynchronosis, or a circadian rhythm sleep disorder in a subject, comprising administering to the subject a compound of claim 55 .
60 . A method of treating or preventing a motor neuron disease or ALS, or slowing or reversing the progression of motor neuron degeneration in a subject, comprising administering to the subject a compound of claim 55 .
61 . A method of improving fertility, treating or preventing infertility, inducing ovulation, increasing sperm count, or increasing lactation, comprising administering to the subject a compound of claim 55 .
62 . A method of treating or preventing kidney damage, acute kidney injury, or kidney disease, or increasing blood flow to the kidneys, comprising administering to the subject a compound of claim 55 .
63 . A method of treating or preventing liver damage or fatty liver, or decreasing the serum level of alanine transaminase (ALT) or aspartate transaminase (AST) in a subject, comprising administering to the subject a compound of claim 55 .Join the waitlist — get patent alerts
Track US2023348521A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.